Literature DB >> 22037799

Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.

Krista A Van Nifterik1, Jaap Van den Berg, Ben J Slotman, M Vincent M Lafleur, Peter Sminia, Lukas J A Stalpers.   

Abstract

Temozolomide (TMZ) is given in addition to radiotherapy in glioma patients, but its interaction with the commonly prescribed antiepileptic drug valproic acid (VPA) is largely unknown. Induction of DNA demethylation by VPA could potentially induce expression of the O(6)-methylguanine-DNA-methyltransferase (MGMT) protein, causing resistance to TMZ and thereby antagonizing its effect. Therefore, this study investigates the interaction between VPA, TMZ, and γ-radiation. Two glioma cell lines were used that differ in TMZ sensitivity caused by the absence (D384) or presence (T98) of the MGMT protein. VPA was administered before (24/48 h) or after (24 h) single doses of γ-radiation; or, after 24 h, VPA treatment was accompanied by a single dose of TMZ for another 24 h. For trimodal treatment the combination of VPA and TMZ was followed by single doses of γ-radiation. In both cell lines VPA caused enhancement of the radiation response after preincubation (DMF(0.2) 1.4 and 1.5) but not after postirradiation (DMF(0.2) 1.1 and 1.0). The combination of VPA and TMZ caused enhanced cytotoxicity (DMF(0.2) 1.7) in both the TMZ-sensitive cell line (D384) and the TMZ-resistant cell line (T98). The combination of VPA and TMZ caused a significant radiation enhancement (DMF(0.2) 1.9 and 1.6) that was slightly more effective than that of VPA alone. VPA does not antagonize the cytotoxic effects of TMZ. Preincubation with VPA enhances the effect of both γ-radiation and TMZ, in both a TMZ-sensitive and a TMZ-resistant human glioma cell line. VPA combined with TMZ may lead to further enhancement of the radiation response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22037799     DOI: 10.1007/s11060-011-0725-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors:  M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

2.  D-1 dopaminergic and beta-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocytoma cell line G-CCM.

Authors:  A J Balmforth; S G Ball; R I Freshney; D I Graham; H B McNamee; P F Vaughan
Journal:  J Neurochem       Date:  1986-09       Impact factor: 5.372

3.  Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models.

Authors:  B Kaina; A Ziouta; K Ochs; T Coquerelle
Journal:  Mutat Res       Date:  1997-11-28       Impact factor: 2.433

4.  Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions.

Authors:  Bisrat G Debeb; Wei Xu; Henry Mok; Li Li; Fredika Robertson; Naoto T Ueno; Jim Reuben; Anthony Lucci; Massimo Cristofanilli; Wendy A Woodward
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

5.  Modulation of radiation response by histone deacetylase inhibition.

Authors:  Prakash Chinnaiyan; Geetha Vallabhaneni; Eric Armstrong; Shyh-Min Huang; Paul M Harari
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-05-01       Impact factor: 7.038

6.  Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines.

Authors:  Jun Fu; Cui-Jie Shao; Fu-Rong Chen; Ho-Keung Ng; Zhong-Ping Chen
Journal:  Neuro Oncol       Date:  2009-10-15       Impact factor: 12.300

7.  Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells.

Authors:  M Ständer; J Dichgans; M Weller
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

8.  Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.

Authors:  Kevin Camphausen; David Cerna; Tamalee Scott; Mary Sproull; William E Burgan; Michael A Cerra; Howard Fine; Philip J Tofilon
Journal:  Int J Cancer       Date:  2005-04-10       Impact factor: 7.396

9.  Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene.

Authors:  J Brennand; G P Margison
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

10.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

View more
  42 in total

1.  The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.

Authors:  Abdel Nasser Hosein; Yi Chieh Lim; Bryan Day; Brett Stringer; Stephen Rose; Richard Head; Leah Cosgrove; Peter Sminia; Michael Fay; Jennifer H Martin
Journal:  J Neurooncol       Date:  2015-02-04       Impact factor: 4.130

Review 2.  Tumor-related epilepsy: epidemiology, pathogenesis and management.

Authors:  Dillon Y Chen; Clark C Chen; John R Crawford; Sonya G Wang
Journal:  J Neurooncol       Date:  2018-05-24       Impact factor: 4.130

Review 3.  Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?

Authors:  Michael Fay; Richard Head; Jennifer Martin
Journal:  J Neurooncol       Date:  2015-05-30       Impact factor: 4.130

4.  Does valproic acid affect tumor growth and improve survival in glioblastomas?

Authors:  Roberta Rudà; Alessia Pellerino; Riccardo Soffietti
Journal:  CNS Oncol       Date:  2016-03-17

5.  DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.

Authors:  Kazuo Okemoto; Kazue Kasai; Benjamin Wagner; Amy Haseley; Hans Meisen; Chelsea Bolyard; Xiaokui Mo; Allison Wehr; Amy Lehman; Soledad Fernandez; Balveen Kaur; E Antonio Chiocca
Journal:  Clin Cancer Res       Date:  2013-09-20       Impact factor: 12.531

6.  Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.

Authors:  Shinichi Watanabe; Yui Kuwabara; Satoshi Suehiro; Daisuke Yamashita; Mamoru Tanaka; Akihiro Tanaka; Shiro Ohue; Hiroaki Araki
Journal:  Eur J Clin Pharmacol       Date:  2016-11-26       Impact factor: 2.953

7.  N-(p-coumaroyl) serotonin inhibits glioblastoma cells growth through triggering S-phase arrest and apoptosis.

Authors:  Diamanto Lazari; George A Alexiou; Georgios S Markopoulos; Evrysthenis Vartholomatos; Entela Hodaj; Ieremias Chousidis; Ioannis Leonardos; Vasiliki Galani; Athanasios P Kyritsis
Journal:  J Neurooncol       Date:  2017-04-01       Impact factor: 4.130

8.  Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.

Authors:  Laurence Booth; Nichola Cruickshanks; Seyedmehrad Tavallai; Jane L Roberts; Matthew Peery; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

9.  Valproic acid use during radiation therapy for glioblastoma associated with improved survival.

Authors:  Christopher A Barker; Andrew J Bishop; Maria Chang; Kathryn Beal; Timothy A Chan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-20       Impact factor: 7.038

10.  Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center.

Authors:  Francisco Helder Cavalcante Felix; Orlandira Leite de Araujo; Karine Martins da Trindade; Nadia Mendonça Trompieri; Juvenia Bezerra Fontenele
Journal:  J Neurooncol       Date:  2013-11-30       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.